

SAFETY DATA SHEET

Finadyne[®] Transdermal



Section 1: Identification of the Substance and Supplier

Product name	Finadyne Transdermal Solution containing 50 mg Flunixin /mL (Equivalent to 83 mg flunixin meglumine /mL).
Recommended use	For the treatment of pain, fever and acute inflammatory conditions in cattle.
Company details	MSD Animal Health, 33 Whakatiki Street, Upper Hutt Phone: 0800 800 543 Fax: 0800 808 100 Website: www.msd-animal-health.co.nz Hours: 8 am – 5 pm, Mon – Fri
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours
Date of preparation	January 2016

Section 2: Hazards Identification

Hazard classifications	6.1E (oral), 6.3B, 8.3A, 9.1D, 9.3C
Priority identifiers	Danger - Keep out of reach of children
Secondary identifier	6.1E May be harmful if swallowed. 6.3B May cause mild skin irritation 8.3A This product is corrosive and may cause eye damage 9.1D May cause long-lasting harmful effect to aquatic organisms. Avoid contamination of any water supply with product or empty container. 9.3C Harmful to terrestrial vertebrates
Risk & Safety Phrases	R22 Harmful if swallowed R38 Irritating to skin

Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
Flunixin meglumine	42461-84-7	8.3%
Pyrrolidone	616-45-5	15%
Levomenthol	2216-51-5	5 – 19%

Section 4: First Aid Measures

Necessary first aid measures	<p>SKIN CONTACT In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.</p> <p>EYE CONTACT In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.</p> <p>INGESTION Rinse mouth and drink a glass of water. DO NOT induce vomiting unless under the direction of a qualified medical professional or Poison Control</p>
-------------------------------------	--

SAFETY DATA SHEET

Finadyne[®] Transdermal

Centre. If symptoms persist, consult a doctor.

Required instructions For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

Notes for medical personnel Probable mucosal damage may contraindicate use of gastric lavage. Flunixin meglumine is a potent Non-Steroidal anti-inflammatory Drug (NSAID), and overexposure may cause gastrointestinal irritation and bleeding, kidney and central nervous system effects.

Section 5: Fire Fighting Measures

Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO ₂), extinguishing powder or water spray
Hazchem code	3Z (contain spillage)
Recommended protective clothing	Wear self-contained breathing apparatus (SCBA) plus protective gloves.

Section 6: Accidental Release Measures

Emergency procedures	Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb/collect spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal. Avoid contamination of any water source with product or empty container.
-----------------------------	--

Section 7: Handling and Storage

Precautions for safe handling	Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.
Regulatory requirements	Signage required where quantities greater than 1000L are present. Emergency Plan required where quantities greater than 10,000L are present.
Handling practices	Avoid contact with skin and eyes. Keep containers adequately sealed during material transfer, transport, or when not in use.
Approved handlers	Not required.
Conditions for safe storage	Store in original container in a cool, dry, ventilated place away from direct heat or direct sunlight. Keep container sealed when not in use. Keep out of reach of children.
Store site requirements	Store in the original bottle and carton at room temperature.
Packaging	PG III

SAFETY DATA SHEET

Finadyne[®] Transdermal

Section 8: Exposure Control/Personal Protection

Workplace exposure standards	No WES is set for this substance at this time.
Application in the workplace	Ensure adequate ventilation. Keep container sealed when not in use.
Exposure standards outside the workplace	No TEL, ADE or PDE is set for this substance at this time No EEL is set for this substance at this time
Personal protection	Wear chemical resistant gloves, facemask or goggles.

Section 9: Physical and Chemical Properties

Appearance	Clear red liquid with amine-line odour
Boiling Point	Not determined
Melting/Softening point	Not determined
Vapour Pressure	Not determined
Specific Gravity	0.99
Solubility (H ₂ O)	Not applicable
Percent Volatiles	Not determined
Evaporation Rate	Not determined

Section 10: Stability and Reactivity

Stability of the substance	Stable under normal conditions.
Conditions to avoid	Avoid open flames and high temperatures
Material to avoid	Avoid food products, strong acids and bases. Oxidizers
Hazardous decomposition products	Nitrogen oxides (NO _x). Hydrogen fluoride (HF)

Section 11: Toxicological Information

Acute effects for individual ingredients only

ORAL	Flunixin Meglumine LD50 53 – 157 mg/kg (rat), 176 to 249 mg/kg (male mouse, female estimate) Pyrrolidone LD50 328 mg/kg (rat) Levomethol LD50 3300 mg/kg (rat)
TEL	No TEL is set for this substance at this time.

Chronic/long term effects for individual ingredients only

SAFETY DATA SHEET

Finadyne[®] Transdermal



Section 12: Environmental Information

Effects for individual ingredients only.

AQUATIC	<p>Pyrrolidone: Water flea: LC50 48 hr: 13.21mg/L Not bioaccumulative and rapidly degradable. Algal: EC50 96 hr 84mg/L Levomenthol: Flathead minnow: LC50 96 hr: 18.9mg/L Not bioaccumulative and not rapidly degradable.</p>
TERRESTRIAL VERTEBRATES	<p>Pyrrolidone: Red wing black bird: LD 50 98 mg/kg</p>
EEL	No EEL is set for this substance at this time.

Section 13: Disposal Considerations

Disposal information	<p>Disposal Dispose of unused product into an appropriate biohazard container or a suitable landfill. Avoid contamination of any water source or the environment with product or empty container.</p> <p>Container Disposal Dispose of empty container by puncturing and burying in a suitable landfill, or if appropriate recycle. Do NOT burn.</p>
-----------------------------	--

Section 14: Transport Information

Relevant information	Not classified as a dangerous good for transport
-----------------------------	--

Section 15: Regulatory Information

Regulatory status	<p>HSNO Approval Code: 100mL and 250mL - HSR100757 1000L - HSR100759. For a full listing of controls see www.epa.govt.nz ACVM registration number: A11281 For conditions of registration see www.foodsafety.govt.nz</p> <p>RESTRICTED VETERINARY MEDICINE</p>
HSNO and ACVM controls	<p>Signage: 1000 Litres Emergency Plan: 10,000 Litres</p>

Section 16: Other Information

Additional information	Finadyne is a registered trademark.
-------------------------------	-------------------------------------

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough Animal Health Limited urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).